| Literature DB >> 26648179 |
Pieter P A Lestrade1,2,3, Jacques F Meis1,2,3, Jan P Arends4, Martha T van der Beek5, Els de Brauwer6, Karin van Dijk7, Sabine C de Greeff8, Pieter-Jan Haas9, Caspar J Hodiamont10, Ed J Kuijper5, Tjalling Leenstra8, Anouk E Muller11, Astrid M L Oude Lashof12, Bart J Rijnders13, Eveline Roelofsen14, Wouter Rozemeijer15, Mathijs Tersmette16, Elizabeth M Terveer5, Cees M Verduin17, Maurice J H M Wolfhagen18, Willem J G Melchers1, Paul E Verweij1,3.
Abstract
A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.Entities:
Keywords: Aspergillosis; azole resistance; treatment
Mesh：
Substances：
Year: 2015 PMID： 26648179 DOI： 10.1111/myc.12440
Source DB: PubMed Journal: Mycoses ISSN： 0933-7407 Impact factor: 4.377